| Dataset | Number of companies | Status | Action |
|---|---|---|---|
| Longevity and age-related biotech | 700+ | Paid-beta | Book demo |
| Wider longevity ecosystem companies (non-biotech) | 800+ | Alpha | Join waitlist |
| Dataset | Number of companies | Status | Action |
|---|---|---|---|
| Longevity and age-related biotech | 700+ | Paid-beta | Book demo |
| Wider longevity ecosystem companies (non-biotech) | 800+ | Alpha | Join waitlist |
In-house teams burn hours stitching together spreadsheets, trial registries, publications and vendor platforms that only partially cover pre/clinical stage drugs and miss emerging assets and off-target longevity potential.
Opportunities are often reactive driven by who knocks on the door or what happens to show up in an inbox – rather than a systematic, deep data-driven view of biotech companies and all of their clinical assets in development.
Generic LLMs and broad data providers (Citeline, GlobalData, Clarivate) are not tuned to longevity biology, struggle with consistent coverage of small and mic-cap biotechs, and don’t reliably surface cross-hallmark adjacencies or GLP-1-style preventive upside.
| Our system | General LLM | Scientific LLM | |
|---|---|---|---|
| Query | DLT | ChatGPT | Perplexity |
| Companies working on MTOR pathway | 25 | 6 | 6 |
| Biotech companies working on advanced aesthetics | 27 | 8 | 6 |
| How many age-related biotechs secured funding within last 3 months? | 40 |
0
“I can’t give you a single reliable number.” |
0
“There is no single comprehensive, real-time tally.” |
| All results with click-throughs to full company profiles |
Query run on 12 January 2026
Track companies by clinical stage
Identify licensing and investment opportunities
Market intelligence and therapeutic trend tracking
Competitive analysis
Out-licensing and in licensing
Therapeutic trends and valuation tracking
Enhanced due diligence
Deal alerts and portfolio competitor tracking
Allocation planning